On February 9, 2017, Bradner, James; Roberts, Justin; Nabet, Behnam; Winter, Georg; Phillips, Andrew J.; Heffernan, Timothy P.; Buckley, Dennis published a patent.Safety of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid The title of the patent was Using heterobifunctional compounds for targeted CAR protein degradation to attenuate adoptive immunotherapy associated adverse inflammation. And the patent contained the following:
Provided are compositions and methods for regulating chimeric antigen receptor immune effector cell, for example chimeric antigen receptor-expressing T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation The chimeric antigen receptor (CAR) construct incorporate a heterobifunctional compound targeted protein or heterobifunctional compound tag, referred to as a dTAG, that allows for reversible targeted CAR protein degradation upon binding to a heterobifunctional compound Provided are heterobifunctional compounds that bind to a ubiquitin ligase through its ubiquitin ligase binding moiety and also bind to the CAR that contains the dTAG through a dTAG Targeting Ligand in vivo. The experimental process involved the reaction of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid(cas: 1216805-11-6).Safety of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid
The Article related to targeted car protein degradation adoptive immunotherapy adverse inflammation attenuation, heterobifunctional compound car protein degradation t cell therapy cancer, Immunochemistry: Adjuvants, Antigens, Haptens, and Vaccines and other aspects.Safety of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem